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Abstract
Objective: To evaluate the effectiveness of drugs used to constrict patent ductus arteriosus (PDA) 
in newborns <28 weeks.
Methods: We performed a secondary analysis of the multi-center PDA-TOLERATE trial 
(NCT01958320). Infants with moderate-to-large PDAs were randomized 1:1 at 8.1±2.1 days to 
either Drug treatment (n=104) or Conservative management (n=98). Drug treatments were 
assigned by center rather than within center (acetaminophen: 5 centers, 27 infants; ibuprofen: 7 
centers, 38 infants; indomethacin: 7 centers, 39 infants).
Results: Indomethacin produced the greatest constriction (compared with spontaneous 
constriction during Conservative management): RR (95% CI) = 3.21 (2.05-5.01)), followed by 
ibuprofen=2.03 (1.05-3.91), and acetaminophen=1.33 (0.55-3.24). The initial rate of 
acetaminophen-induced constriction was 27%. Infants with persistent moderate-to-large PDA after 
acetaminophen were treated with indomethacin. The final rate of constriction after acetaminophen
±indomethacin was 60% (similar to the rate in infants receiving indomethacin-alone (62%)).
Conclusion: Indomethacin was more effective than acetaminophen in producing ductus 
constriction.
Introduction:
Most preterm infants ≥28 weeks of gestation close their patent ductus arteriosus (PDA) 
spontaneously by the end of the first postnatal week (1, 2). In contrast, 50-70% of infants 
<28 weeks of gestation, have a moderate-to-large PDA shunt that persists for weeks after 
birth (3). Indomethacin and ibuprofen are currently the only labeled drugs to promote 
constriction of the PDA. In 2011, Hammerman et al reported that acetaminophen was an 
effective drug for constricting the PDA in preterm infants (4). The presumed mechanism of 
action was decreased prostaglandin production within the ductus wall through competitive 
inhibition of the peroxidase component of prostaglandin endoperoxide H2 synthase (5, 6).
Acetaminophen (with its presumed superior safety profile) has the potential to be an 
excellent substitute for the two currently labeled drugs if its efficacy can be shown to be 
comparable. To date, acetaminophen has been examined in 10 published randomized clinical 
trials (RCTs). These RCTs and subsequent meta-analyses suggest that acetaminophen’s 
efficacy is comparable to the efficacy of indomethacin and ibuprofen (7-19). Unfortunately, 
only one of the 10 RCTs (10) exclusively enrolled infants that were at high risk for having a 
persistent PDA – namely, those born before 28 weeks of gestation. The 9 RCTs that included 
infants born ≥28 weeks of gestation (where the PDA was likely to close spontaneously by 
the end of the first week (1, 2)) ran the risk of biasing the PDA outcome towards the null 
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hypothesis when comparing acetaminophen with indomethacin or ibuprofen. Therefore, we 
designed the following study, in infants born before 28 weeks of gestation, to determine if 
acetaminophen was as effective as indomethacin in constricting the PDA.
The PDA-TOLERATE trial (NCT01958320, Clinicaltrials.gov) was a RCT designed to 
determine if routine use of drugs to promote closure of moderate-to-large PDAs, that were 
still present at the end of the first week in infants born below 28 weeks of gestation, would 
reduce neonatal morbidity compared with a Conservative approach that delayed PDA drug 
use for at least another 7–10 days (20). Infants in the PDA-TOLERATE trial were 
randomized to either routine Early drug treatment to constrict the PDA (where they received 
either acetaminophen, ibuprofen, or indomethacin as their initial drug treatment) or to 
Conservative treatment. We performed the following secondary analysis of the PDA-
TOLERATE trial (20) to compare the rates of PDA constriction in infants <28 weeks of 
gestation who received either no treatment (the Conservative group) or received treatment 
with indomethacin, ibuprofen or acetaminophen. Our goal was to determine if 
acetaminophen was as effective as indomethacin in constricting the PDA. Since recent 
studies have shown that the only PDA shunts that are associated with neonatal morbidity are 
moderate-to-large shunts, (“small” PDA shunts” do not appear to have any association with 
morbidity (21, 22)), we tested the hypothesis that acetaminophen was as effective as 
indomethacin in producing “successful ductus constriction” by eliminating the presence of 
moderate-to-large PDA shunts (see Statistical analysis below for definition of “successful 
ductus constriction”).
Methods:
Our study utilized data from the 202 patients enrolled in the PDA-TOLERATE trial 
(NCT01958320), a prospective randomized controlled trial conducted between January 2014 
and June 2017 at 17 international sites to compare the effects of Early Routine treatment of 
moderate-to-large PDAs with a Conservative approach that delayed treatment to promote 
constriction of the PDA until prespecified respiratory and hemodynamic “Rescue” criteria 
were met. Full details of the PDA-TOLERATE trial including screening, echocardiographic 
analyses, and enrollment have been published elsewhere (20). Institutional review board 
approval and written informed parental consent were obtained before patient enrollment. All 
procedures followed were in accordance with the ethical standards of the institutional review 
boards.
Infants <28 weeks of gestation were enrolled in the PDA-TOLERATE trial if they were 
between 6–14 days old, had a moderate-to-large PDA (see Echocardiographic studies), and 
were receiving greater than minimal respiratory support (20). Eligible infants were excluded 
from participation if they had received prior treatment with indomethacin or ibuprofen, had 
chromosomal anomalies, congenital or acquired gastrointestinal anomalies, prior episodes of 
necrotizing enterocolitis or intestinal perforation, active pulmonary hemorrhage at the time 
of enrollment, or contraindications to the use of indomethacin or ibuprofen (e.g., 
hydrocortisone or dexamethasone administration within preceding 24 hours, urine output < 1 
ml/kg/h during preceding 8 hours, serum creatinine >1.6 mg/dl, platelet count <50, 000/
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mm3, or abnormal coagulation studies). Sixteen of the 17 centers also excluded infants if 
they needed inotropic support for hypotension at the time of enrollment (20).
Echocardiographic studies in the PDA-TOLERATE trial were performed according to the 
study protocol and schedule for exams (20) and included two-dimensional imaging, M-
mode, color flow mapping and Doppler interrogation as previously described (23, 24). A 
moderate-to-large PDA was defined by a ductus internal diameter ≥ 1.5mm (or PDA:left 
pulmonary artery diameter ratio ≥0.5) and one or more of the following echocardiographic 
criteria: a) left atrium-to-aortic root (LA/Ao) ratio ≥1.6, b) ductus flow velocity ≤2.5m/sec 
or mean pressure gradient across the ductus ≤8 mm Hg, c) left pulmonary artery diastolic 
flow velocity > 0.2 m/sec, and/or d) reversed diastolic flow in the descending aorta. Ductus 
that did not meet these criteria were considered to be “constricted” (small or closed) and not 
eligible for enrollment or treatment.
Enrolled infants (n=202) were randomized to one of two groups: Early drug use to promote 
PDA constriction (n=104) or a Conservative approach (n=98) that delayed drug use until 
prespecified respiratory and hemodynamic “Rescue” criteria were met. Randomization was 
stratified by gestational age (230/7-256/7 or 260/7–276/7) and by center. Block randomization 
at a 1:1 ratio occurred at each site. Study randomization was blinded, but treatment 
allocation by the medical team was not blinded because treatment blinding would have 
required unnecessary clinical procedures and blood sampling for infants in the Conservative 
group. The cardiologists or echocardiography-trained neonatologists reading the 
echocardiograms were unaware of the infants’ treatment assignments.
Infants randomized to the Conservative group (n=98) were not eligible for drug treatment to 
promote PDA constriction until at least 7 days after randomization and required one or more 
of the prespecified “Rescue” criteria before Rescue treatment could be given (see Rescue 
criteria below).
Infants randomized to the Early drug treatment group (n=104) received one of three drug 
treatment protocols. We anticipated that there would be limited patient enrollment at each 
study center and felt that it was unlikely that a within-center randomization scheme would 
insure equal distribution of the three drugs among the enrollees at each of the study centers. 
Therefore, drug treatments were assigned by center rather than within center, and the relative 
effectiveness of each drug was determined by comparing its effectiveness with reference to 
spontaneous closure. One drug treatment protocol was used at each site (one site used each 
of the three protocols during three sequential study periods). The acetaminophen protocol 
was used at 5 centers, the ibuprofen protocol at 7 centers, and the indomethacin protocol at 7 
centers.
Initial drug treatment protocols for the Early treatment group were:
Acetaminophen protocol: 20 mg/kg acetaminophen loading dose followed by a maintenance 
dose of 12.5 mg/kg every 6 hours for 19 maintenance doses (over 5 days). Acetaminophen 
was administered either enterally (3 infants) or intravenously (24 infants). A “trough” 
acetaminophen concentration was obtained 30 minutes before the 3rd maintenance dose. If 
the concentration was less than 15 mg/L, the subsequent maintenance doses were increased 
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to 15 mg/kg and a “trough” acetaminophen concentration was obtained before the 3rd new 
maintenance dose. Twenty-five of the 27 infants required 15 mg/kg for maintenance doses 
4–19. An echocardiogram was performed 24–48 hours after completing the initial 
acetaminophen treatment course. If the PDA was still moderate-to-large after the initial 
acetaminophen course the infant was treated with indomethacin as a backup Early drug 
treatment (see indomethacin protocol).
Ibuprofen protocol: 10 mg/kg ibuprofen loading dose followed by a maintenance dose of 5 
mg/kg every 24 hours for up to 4 maintenance doses (4 infants received 20 mg/kg loading 
and 10 mg/kg maintenance doses). Ibuprofen was administered either enterally (14 infants) 
or intravenously (24 infants). Three of the seven ibuprofen centers administered the 
intravenous acetaminophen protocol simultaneously with the ibuprofen protocol. The results 
from infants who received acetaminophen and ibuprofen simultaneously were grouped 
together for analysis with the results from infants who received ibuprofen alone since a 
recent pilot study was unable to detect a difference in PDA closure when intravenous 
acetaminophen and ibuprofen were administered simultaneously (25). An echocardiogram 
was performed 24–48 hours after completing the initial ibuprofen treatment course. If the 
PDA was still moderate-to-large after the initial ibuprofen course the infant could be treated 
with indomethacin as a backup Early drug treatment (see indomethacin protocol).
Indomethacin protocol: 0.2 mg/kg indomethacin intravenous doses at 0, 12, 24, 48 hours (4 
doses ). An echocardiogram was performed within 24 hours after the 4th dose. If the ductus 
was still open, doses 5 and 6 were administered at 72 hours and 96 hours and a repeat 
echocardiogram was performed 24–48 hours after completing the last dose of indomethacin.
Seven-to-ten days after randomization, a repeat echocardiogram was performed on all 
infants in both the Conservative and Early treatment groups. Infants with a “constricted” 
(small or closed) ductus were examined daily for a change in clinical symptoms indicative of 
a reopened, moderate-to-large PDA (systolic murmur or hyperdynamic precordium). If 
either of these occurred, an echocardiogram was performed within 24 hours. In addition, 
routine echocardiograms were performed every 2–3 weeks until ductus closure or hospital 
discharge in infants with a “constricted” PDA. Infants with a persistent moderate-to-large 
PDA after the first week were followed with frequent (every 7–14 days) echocardiograms to 
determine when ductus constriction occurred. Echocardiograms were performed until ductus 
closure or hospital discharge.
Infants in the Conservative group, with a persistent moderate-to-large PDA after the first 
week, were eligible for rescue drug treatment to promote PDA constriction if they met one 
or more prespecified “Rescue” criteria which included: inotrope-dependent hypotension that 
required continuous dopamine support for at least 3 days (with hypotension defined as mean 
blood pressure at least 2–3 mmHg below the infant’s postmenstrual age), or oliguria (<2 
ml/kg/hour) that persisted for at least 2 days (with no obvious cause, other than the moderate 
PDA, to explain the condition), or respiratory support that surpassed prespecified ventilation 
and FiO2 requirements (see reference (20) for criteria). The “Rescue” drug protocol at a site 
was the same drug protocol used for the “Early treatment” group at that site. Neonatologists 
caring for infants in the Conservative group were not required or encouraged to treat infants 
Liebowitz et al. Page 5
J Perinatol. Author manuscript; available in PMC 2019 September 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
who met “Rescue” criteria. Rather, the “Rescue” criteria served as the threshold or minimal 
criteria that were needed before infants in the Conservative group could be eligible for 
closure treatment. Infants in the Early treatment group, with persistent moderate-to-large 
PDAs after the first week, could receive rescue treatment at the clinician’s judgment, 
whether or not they met “Rescue” criteria.
“Trough” serum acetaminophen concentrations were measured by a turbidimetric inhibition 
immunoassay performed on a Beckman DxC 800 instrument (Beckman Coulter, Inc.) in the 
hospitals’ clinical laboratories.
A Data Safety Monitoring Board performed regular interim analyses and reviewed all 
serious adverse events (see reference (20)).
Statistical analysis
Our study’s primary goal was to compare the incidence of “successful spontaneous ductus 
constriction”, at 7–10 days after enrollment in the Conservative group, with the incidence of 
“successful ductus constriction” after the initial acetaminophen, ibuprofen, or indomethacin 
treatments (prior to the use of any backup drug treatment with indomethacin). “Successful 
ductus constriction” was defined as ductus that were small or closed on the echocardiogram 
performed after the initial drug protocol (or at 7–10 days after enrollment in the 
Conservative group). Ductus that were initially small or closed after treatment (or at 7 days 
after enrollment in the Conservative group) but later reopened and became moderate-to-large 
again were not considered to have achieved “successful constriction”.
All analyses were performed with the statistical software STATA (StataCorp. 2015. Stata 
Statistical Software: Release 14. College Station, TX: StataCorp LP). Chi-Squared tests 
were used to compare the treatment groups for categorical variables. For continuous 
variables, analysis of variance was used to compare groups for parametric variables and 
Kruskal-Wallis equality-of-populations rank test to compare groups for non-parametric 
variables. Generalized estimating equations were used to model the relationship between the 
initial drug or Conservative management and the response to treatment adjusted for potential 
confounders. Based on previous studies (26-32) showing an association between initial 
ductus closure and gestational age, antenatal betamethasone exposure and race, we decided a 
priori to include these variables in the model. We specified a Poisson distribution so that we 
could directly estimate relative risks from this model. Since the type of drug received was 
highly correlated to the study site, we adjusted standard errors of the model for clustering by 
study site. We specified an exchangeable correlation and used robust standard errors. 
STATA’s contrast command was used to perform a test of trend across the categories of 
initial drug protocols to determine if there was a significant linear trend.
Results:
Our goal was to determine the incidence of “successful ductus constriction” after 
Conservative treatment (spontaneous constriction at 7–10 days) or after initial drug 
treatment with acetaminophen, ibuprofen, or indomethacin. Two hundred and two infants 
were enrolled in the PDA-TOLERATE trial and randomized between Conservative treatment 
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(n=98) and Early treatment (n=104) approaches. Early drug treatment protocols were 
assigned by center and the relative effectiveness of each drug was determined by comparing 
its effectiveness with reference to spontaneous constriction. The acetaminophen protocol 
was used at 5 centers (27 infants), the ibuprofen protocol at 7 centers (38 infants), and the 
indomethacin protocol at 7 centers (39 infants) (Figure 1). Six infants died before drug 
treatment and echocardiographic analysis could be completed (Figure 1). Prenatal and 
neonatal demographic characteristics were similarly distributed among the 196 surviving 
infants in the Conservative and Early treatment study groups except for the incidences of 
Caucasian race and early onset bacteremia (Table 1).
The frequencies of spontaneous or initial drug-induced constriction are shown in Figure 1. In 
this population of infants delivered before 28 weeks of gestation, who still had a moderate-
to-large PDA at the end of the first week, only 20% constricted their ductus spontaneously 
during the next 7–10 days (Figure 1). After adjusting for gestational age, antenatal 
betamethasone exposure and Caucasian race, we found a significant (p=0.001) linear test of 
trend for the rate of ductus constriction among the study groups with indomethacin having 
the greatest effectiveness for ductus constriction (relative risk compared with Conservative 
treatment (RR, 95% CI) = 3.21 (2.05–5.01)), followed by ibuprofen (2.03 (1.05–3.91)) and 
acetaminophen (1.33 (0.55–3.24)) (Table 2).
In our study acetaminophen produced a non-significant increase in the rate of constriction 
compared with the rate of spontaneous constriction after Conservative treatment. There was 
no significant difference in the “trough” acetaminophen concentrations (after the highest 
dose of acetaminophen) between infants with a constricted ductus (mean±sd: 16.1±3.2 
mg/L; range: 12–21) and those with a persistent moderate-to-large PDA (15.5±3.7 mg/L; 
range: 10–22). The “trough” acetaminophen concentrations also were similar after 
intravenous and enteral acetaminophen administration (intravenous (n=23): 15.7±3.4 mg/L 
(10-22); enteral (n=3): 15.7±4.7 mg/L (14-21)). Infants who were treated initially with 
acetaminophen and still had a persistent moderate-to-large PDA after treatment were 
subsequently treated with indomethacin (see acetaminophen protocol, Methods). The final 
rate of constriction in the acetaminophen group (after either successful constriction with 
acetaminophen-alone or after the combination of acetaminophen followed by indomethacin) 
was 60%.
Forty-three infants in the Conservative treatment group received Rescue drug treatment to 
promote PDA closure at 21±8 days postnatal age. The rates of ductus constriction after 
Rescue drug treatment were similar to the rates of constriction after Early Drug treatment 
(Figure 1). “Trough” acetaminophen concentrations after Rescue acetaminophen treatment 
were similar in infants with a constricted ductus (mean±sd: 17.0±4.3 mg/L; range: 10–21) 
and those with a persistent moderate-to-large PDA (19.5±5.0 mg/L; range: 13–29). The 
“trough” acetaminophen concentrations also were similar after Rescue intravenous and 
Rescue enteral acetaminophen administration (intravenous (n=10): 17.7±5.4 mg/L (10-29); 
enteral (n=5): 20.5±2.1 mg/L (18-23)), as were the rates of ductus constriction (intravenous: 
40%; enteral: 40%). The overall rate of ductus constriction after either Early drug treatment 
or Rescue drug treatment was significantly higher for indomethacin (31/50 (62%)) when 
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compared with either ibuprofen (20/50 (40%), p<0.05) or acetaminophen (13/41 (32%), 
p<0.01).
Discussion:
In our multi-center RCT the rate of spontaneous ductus constriction, among babies delivered 
before 28 weeks of gestation, who still had a moderate-to-large PDA at the end of the first 
week, was only 20% during the 7–10 days after enrollment. During the same time interval 
indomethacin treatment was associated with the greatest rate of constriction (62%), whereas 
acetaminophen was associated with the lowest rate (27%). Although our findings are 
consistent with previous preclinical in vitro (6) and in vivo (33, 34) studies they differ from 
the 10 previously published RCTs that consistently found acetaminophen to be as effective 
as indomethacin and ibuprofen in constricting the ductus (7-19).
Our study design differed from the prior RCTs in several respects. Although the centers in 
our study randomized Early drug treatment and Conservative management in a 1:1 ratio, 
only one of the three drug treatment protocols was used at each center. Therefore, we 
determined the relative effectiveness of the different drug treatments by comparing their 
effectiveness with reference to spontaneous closure. We think it is unlikely that centers using 
acetaminophen had a lower rate of responsiveness to prostaglandin synthase inhibitors than 
centers using indomethacin. As part of the acetaminophen protocol, infants whose PDA 
failed to constrict after acetaminophen treatment were subsequently treated with 
indomethacin and their combined rate of acetaminophen ± indomethacin constriction was 
60% (which was similar to the rate of ductus constriction at centers that used indomethacin-
alone (62%)).
Our study exclusively enrolled infants <28 weeks of gestation. In contrast, only one of the 
prior RCTs (10) enrolled infants that were exclusively below 28 weeks of gestation. The 
remaining studies enrolled more mature infants. The effectiveness of drugs that promote 
ductus constriction depends on the infant’s developmental age at the time of treatment (32). 
Therefore, some of the different outcomes between our trial and the prior trials may be due 
to the different developmental ages of the study populations.
Although the final acetaminophen dosing schedule in our trial was similar to the one used in 
prior RCTs, the route of acetaminophen administration differed significantly between our 
trial and the previous trials (88% received intravenous dosing in our trial; 80% received 
enteral dosing in the prior RCTs). To date, only two small trials have compared the effects of 
intravenous and enteral acetaminophen administration on ductus constriction and reported 
opposing results (6, 35). In our study, there were no differences in “trough” acetaminophen 
concentrations or rates of ductus constriction between the two routes of administration.
Recently Bin-Nun et al (36), using a similar acetaminophen dosing schedule as ours, 
reported that serum acetaminophen concentrations (measured 4 hours after an enteral dose) 
predicted the ductus’ contractile response to treatment. They reported that acetaminophen 
concentrations ≥20 mg/L were needed to produce ductus constriction. Although we used a 
similar dosing schedule as Bin-Nun et al, we found lower trough acetaminophen 
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concentrations. The average “trough” acetaminophen concentrations in our study were 
16.6±4.1 mg/L (range: 10–29) (measured 5.5 hours after an enteral or intravenous dose). We 
also found no differences in the “trough” acetaminophen concentrations between infants 
who constricted their ductus and those who did not. Future pharmacodynamics trials will be 
needed to determine if serum acetaminophen concentrations can predict ductus constriction 
and whether these concentrations can be achieved safely by increasing enteral or intravenous 
dosing.
Our trial had several limitations. We anticipated that there would be limited enrollment at 
each study center and felt that it was unlikely that a within-center randomization scheme 
would insure equal distribution of the three drugs among the enrollees at each of the study 
centers. Therefore, drug treatments to promote PDA closure were assigned by center rather 
than within center, and the relative effectiveness of each drug was determined by comparing 
its effectiveness with reference to spontaneous closure. This limited our ability to compare 
one drug treatment directly with another. The relatively small number of infants in each of 
the drug treatment groups also limited the overall power of our analysis. Although both the 
study treatment randomization (to Early or Conservative treatment) and the reading of the 
study echocardiograms were performed in a blinded manner, the medical teams were aware 
of the treatments that infants received which may have affected some of the other study 
outcomes. The PDA-TOLERATE trial allowed for backup indomethacin therapy and Rescue 
drug treatment when the initial drug treatment failed to constrict the ductus: 44% of the 
Conservative group received Rescue drug treatment to promote PDA closure and 37% of the 
Early drug treatment group received backup drugs that differed from the initial drugs they 
were treated with. This made it impossible to evaluate potential morbidities that might be 
due solely to the Conservative management or the initial drug treatments.
In addition to our findings related to the effectiveness of different drug treatment protocols, 
we made several other observations that may add to our understanding of drug treatment to 
promote PDA constriction. Prior studies have shown that an infant’s gestational age, race, 
and prior exposure to betamethasone play a significant role in determining the rate of drug-
induced closure during the first days after birth (26-32). In the current study, we found that 
these risk factors no longer play a role in the rate of ductus constriction when treatment is 
started after the first week (Table 2). Similarly, while drug efficacy appears to decline during 
the course of the first postnatal week (37, 38), beyond the first week any additional decline 
in drug potency appears to be much less noticeable. We found that the rates of ductus 
constriction after routine drug treatment at 8.1±2.1 days were similar to the rates after 
Rescue drug treatment at 21±8 days (Figure 1).
In conclusion, we found that acetaminophen was less effective than indomethacin when used 
as initial drug treatment at the end of the first week to produce ductus constriction in infants 
<28 weeks of gestation. The current interest in acetaminophen for PDA constriction is based 
on the thought that if effective, acetaminophen might have fewer side effects than 
indomethacin or ibuprofen. Recently, concern has been raised about acetaminophen’s 
presumed superior safety profile based on reports of neurocognitive impairment after 
prenatal exposure (39). Unfortunately, information about acetaminophen’s long-term effects 
in this population is lacking. Since our study questions the relative efficacy of 
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acetaminophen in producing ductus constriction, it underscores the need for appropriate 
pharmacodynamic and follow-up studies examining both the route and dose of 
acetaminophen before routine use can be recommended in this vulnerable population.
Data Availability:
After de-identification individual participant data that underlie the results reported in this 
article will be available to researchers who provide a methodologically sound proposal. 
Proposals should be directed to clymanr@ucsf.edu. To gain access, data requestors will need 
to sign a data access agreement.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Flow diagram of patient distribution and ductus outcomes among Conservative management 
and Drug treatment groups.
No RX*: Thirty infants with a moderate-to-large PDA did not receive rescue treatment 
because they either did not meet the Rescue clinical criteria (n=17) or the clinical team 
chose not to treat them despite having met Rescue criteria (n=13) (see Methods). 26/30 
(87%) constricted their ductus spontaneously by the time of discharge from the hospital.
Note: among the 38 infants treated with Early Rx Ibuprofen 34 received a loading dose of 10 
mg/kg followed by maintenance doses of 5 mg/kg. Four infants received 20 mg/kg loading 
and 10 mg/kg maintenance doses. Only one of the four (25%) infants in the high dose group 
had successful ductus constriction.
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Table 1:
Baseline demographic and clinical characteristics of babies in the Conservative and Early Drug Treatment 
groups.
Conservative
(n=98)
Early Treatment
(n=98)
Acetaminophen
(n=26)
Ibuprofen
(n=35)
Indomethacin
(n=37)
p-
value a
Prenatal Variables:
Maternal age – years (m±sd) 29.9±6.4 28.3±5.9 28.7±6.2 29.3±6.6
Multiple gestation - % 39 27 17 24 0.075
Premature rupture of membranes - % 20 23 20 16
Preeclampsia - % 19 15 11 8
Chorioamnionitis - % 16 15 14 14
Diabetes - % 7 4 0 0
Caesarian section - % 70 62 60 78
Betamethasone ≥24hr - % 64 65 60 65
 
Neonatal Variables prior to Enrollment:
Gestation – weeks (m±sd) 25.9±1.1 25.6±1.5 25.6±1.2 25.9±1.1
Gestation ≤256/7 weeks - % 52 53.9 51.4 56.8
Birthweight – grams (m±sd) 810±179 778±176 809±170 777±140
Small for Gestation - % 9 4 9 3
Male - % 44 50 49 43
Caucasian - % 55 50 69 32 0.019
Apgar (5-minutes) ≤5 - % 28 31 20 32
Apgar (10-minutes) ≤5 - % 7 8 11 5
Delivery room intubation - % 71 65 74 62
Intubated at 24 hours - % 70 54 60 59
Intubated at enrollment - % 48 54 40 59
Surfactant - % 94 92 91 84
Dopamine prior to enrollment - % 35 23 35 41
Dopamine at enrollment - % 6 4 6 8
Pulmonary Hemorrhage prior to enrollment - % 3 12 3 3
Early onset bacteremia (≤3days) - % 0 0 6 11 0.007
sIVH prior to enrollment - % 11 12 26 16
Age at enrollment – days (m±sd) 8.3±2.3 8.0±2.4 7.6±1.8 8.5±2.2
a,p-value are presented only for values ≤0.10
Pulmonary hemorrhage was defined as: gross blood in the endotracheal tube, new infiltrates on the chest radiograph, and deterioration in infant’s 
respiratory status.
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Table 2:
Adjusted relative risk and 95% confidence interval of the relationships between the individual treatment 
groups and ductus constriction. The potential confounders in the model were: gestational age (<26 0/7 weeks 
or ≥26 0/7 weeks), antenatal betamethasone exposure (<24 hours or ≥24 hours), and Caucasian race (yes or 
no).
Relative Risk 95% CI p-value a
Treatment Group
Conservative 1.0
Acetaminophen 1.33 (0.55 – 3.24)
Ibuprofen 2.03 (1.05 – 3.91) 0.035
Indomethacin 3.21 (2.05 – 5.01) <0.001
Gestation ≥26 0/7 weeks 1.21 (0.85 – 1.70)
Betamethasone ≥24 hours 0.78 (0.58 – 1.05)
Caucasian 1.14 (0.75 – 1.74)
a,p-value are presented only for values ≤0.10
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